Ayman Iskander, MD
Cardiovascular Disease · Liverpool, NYNPI 1972599728
Payments from drug & device makers
Across 515 payments — averaging $2560.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$972K
- CSL Behring$93K
- Boehringer Ingelheim International GmbH$88K
- Boehringer Ingelheim Pharma GmbH & Co.kg$81K
- W. L. Gore & Associates, Inc.$52K
- Edwards Lifesciences$25K
- plus $7K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 97 | $972,314 |
| CSL Behring | 46 | $92,854 |
| Boehringer Ingelheim International GmbH | 7 | $88,488 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $81,326 |
| W. L. Gore & Associates, Inc. | 14 | $52,137 |
| Edwards Lifesciences | 148 | $24,621 |
| Inari Medical, Inc. | 6 | $1,398 |
| Abbott | 22 | $1,086 |
| Boston Scientific | 16 | $832 |
| Abiomed | 17 | $603 |
| Amgen | 22 | $417 |
| AstraZeneca | 17 | $382 |
| Penumbra, Inc. | 6 | $356 |
| Thrombolex, Inc. | 4 | $350 |
| Johnson & Johnson | 15 | $217 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $206 |
| Pfizer | 11 | $175 |
| Merck | 9 | $160 |
| Actelion Pharmaceuticals US, Inc. | 6 | $122 |
| Lexicon Pharmaceuticals, Inc. | 5 | $90 |
| Novartis | 5 | $88 |
| Biotronik Inc. | 2 | $76 |
| Atricure, Inc. | 1 | $73 |
| Shockwave Medical, Inc | 2 | $69 |
| Boehringer Ingelheim | 3 | $69 |
| Bayer | 3 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Philips North America LLC | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Cardiovascular Systems Inc. | 1 | $23 |
| Angiodynamics, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,318,781 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Liverpool
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.